Appointments at Agilent Technologies, iBio, Sanofi Aventis and Q Chip – People on the move

By Nick Taylor

- Last updated on GMT

Related tags Chief financial officer Management occupations Board of directors Vice president

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Agilent Technologies, iBio, Sanofi Aventis and Q Chip.

Adrian Dillon​ is resigning from his position as executive vice president (EVP), finance and administration, and chief financial officer at Agilent Technologies​, effective April 1.

Following Dillon’s resignation, Didier Hirsch​, currently VP, corporate controllership and tax, will become acting chief financial officer. Hirsch has worked at Agilent since it formed. Before this he held various positions at Hewlett-Packard.

iBio ​has named Vidadi Yusibov​ as chief scientific officer. Yusibov is executive director of the Fraunhofer USA Center for Molecular Biotechnology (CMB) in Newark, Delaware, a role he will continue after joining iBio.

UK-based Q Chip​, a biotech developing sustained release formulations, has appointed Tony Mills​ to its board of directors. Mills has more than 20 years experience in biotech commercialisation at companies including Peptide Therapeutics, BioVex and Phynova.

VGXI​ has made three appointments. Firstly, David Weiner ​has joined the company’s scientific advisory board. Weiner is chairman of Inovio Biomedical’s scientific advisory board and professor of pathology and laboratory medicine at the University of Pennsylvania, US.

Also, Sandra Jones ​has been named as director of validation and David Colvin ​has been appointed as key account manager. Jones joins from Beckman-Coulter and Colvin from Merck & Co.

Yehong Zhang ​has been named as president of Simcere Pharmaceutical Group​. Zhang has 18 years in the healthcare industry at companies including Merck & Co, McKinsey and IMS.

Sanofi Aventis ​has nominated Catherine Brechignac​ to its board of directors. Shareholders will be asked to approve Brechignac’s appointment in May. If approved, Brechignac will replace Jean-Marc Bruel who is not seeking reappointment to the board.

Related topics Markets & Regulations

Related news

Show more